Phase Ib study with expansion of ibrutinib, lenalidomide, and rituximab in patients with relapsed/refractory central nervous system lymphoma
R2I was tolerated well with high response rates and a short time to best respond. Median PFS was limited but 1/3 of patients had durable responses >12 months. This trial was registered at www.clinicaltrials.gov (NCT03703167).
Authors
- Jasmine H. Francis (ORCID: https://orcid.org/0000-0002-7637-3108)
- Katherine S. Panageas (ORCID: https://orcid.org/0000-0002-6591-604X)
- Lisa Marie DeAngelis (ORCID: https://orcid.org/0000-0002-6290-7818)
- Rachna Malani (ORCID: https://orcid.org/0000-0003-2038-8738)
- Christian Grommes (ORCID: https://orcid.org/0000-0002-7485-0441)
- Elena Pentsova (ORCID: https://orcid.org/0000-0001-5854-0251)
- Robert J. Young (ORCID: https://orcid.org/0000-0001-7003-3017)
- Joe Sammy Mendez (ORCID: https://orcid.org/0000-0002-9138-8658)
- Anna F. Piotrowski (ORCID: https://orcid.org/0000-0003-0058-8476)
- Lauren R. Schaff (ORCID: https://orcid.org/0000-0002-4664-670X)
- Ingo K. Mellinghoff (ORCID: https://orcid.org/0000-0002-4347-8149)
- Igor T. Gavrilovic (ORCID: https://orcid.org/0000-0001-9104-6132)
- Sarah Tang (ORCID: https://orcid.org/0000-0002-9148-7525)
- Vaios Hatzoglou (ORCID: https://orcid.org/0000-0003-0252-0694)
- Anne S. Reiner (ORCID: https://orcid.org/0000-0002-1258-6112)
- Thomas Kaley (ORCID: https://orcid.org/0000-0002-2540-8518)
- Andrew Lin (ORCID: https://orcid.org/0000-0002-7446-142X)
- Laura Quinn (ORCID: https://orcid.org/0000-0001-9660-4631)
- Craig Nolan (ORCID: https://orcid.org/0000-0003-3534-4615)
- Venissala Wongchai (ORCID: https://orcid.org/0009-0009-0981-8849)
- Ashley Gonzalez (ORCID: https://orcid.org/0009-0005-4210-3264)
- Juli T. Madzsar
- Laura Breakey
- Laleh Emadi-Paramkouhi
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Cornell University (US)
- University of Utah (US)
- Huntsman Cancer Institute (US)
Publication Details
- Journal
- Neuro-Oncology
- Published
- 2025-04-22
- DOI
- https://doi.org/10.1093/neuonc/noaf104
- Citations
- 2
- Primary Topic
- CNS Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.78
Funders
- National Cancer Institute
- National Institute of Neurological Disorders and Stroke